Lunit Presents 7 Studies on AI Biomarker Applications at ASCO

Medical AI company Lunit announced on the 25th that it will present seven research results utilizing its AI biomarker platform, Lunit Scope, at the 2024 American Society of Clinical Oncology (ASCO 2024), held in Chicago, USA, from May 31 to June 4.

Founded in 1965, ASCO is considered one of the world's top three cancer societies along with the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO). Every year, more than 40,000 academic and industry professionals gather to share the latest research and industry trends. Lunit has been participating annually in ASCO since 2019, presenting its research achievements.

At this conference, Lunit will present key studies including ▲ Identification of human epidermal growth factor receptor 2 (HER2) ultra-low expression breast cancer patient groups using AI ▲ Poster presentation on predicting immune checkpoint inhibitor (ICI) treatment response in non-small cell lung cancer patients based on pathological image and computed tomography (CT) scan data analysis.

In addition, Lunit will present ▲ Prediction of recurrence risk and disease-free survival in hormone receptor-positive early breast cancer patients using AI ▲ Analysis of immune phenotypes and immune checkpoint inhibitor responses in East Asian and Western melanoma patients, focusing on differences between the two populations ▲ AI-based tertiary lymphoid structure analysis to predict immune checkpoint inhibitor treatment response in non-small cell lung cancer patients ▲ Comparative analysis of immune-chemotherapy combination therapy and immune monotherapy in non-small cell lung cancer patients based on individual patient-level survival data reported in clinical trials.

Seobum Seok, CEO of Lunit, said, “We have continuously demonstrated the excellent technology and clinical outcomes of Lunit Scope through world-renowned conferences such as ASCO. We will devote ourselves to research and development so that Lunit Scope can be used as the next-generation essential biomarker platform for immune checkpoint inhibitor treatment decisions, and we will continue to expand our product lineup to be applicable to a wider range of cancer types.”

This content was produced with the assistance of AI translation services.